Atherosclerosis and the genetic basis of lipoprotein disease

Best Practice and Research: Clinical Anaesthesiology

Volumn 15, Issue 2, 2001, Pages 169-183

  Rother, Anne L ^a   Collard, Charles D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Apolipoproteins; Cholesterol; Coronary artery disease; Gene therapy; Review; Vascular disease

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHYLOMICRON; CYCLOSPORIN; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; THIAZIDE DIURETIC AGENT; VERY LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; ENZYME POLYMORPHISM; GENE TARGETING; GENE THERAPY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIPID METABOLISM; LIPID TRANSPORT; LIPOPROTEIN DEFICIENCY; LONG TERM CARE; MASS SCREENING; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; REVIEW; SCHOOL CHILD; VASCULAR DISEASE;

EID: 0034906264     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1053/bean.2001.0150     Document Type: Article

References (61)

1. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents
2. Atherosclerosis
3. The genetic basis of atherosclerosis
4. Atherosclerosis: An inflammatory disease
5. Lipoproteins and atherogenesis
6. Plasma triglyceride-rich lipoprotein and high density lipoprotein disorders associated with atherosclerosis
7. Lipoprotein physiology
8. Overview of plasma lipid transport
9. Pathophysiology and management of low high-density lipoprotein cholesterol
10. Atheroprotective mechanisms of HDL
11. New risk factors for coronary heart disease
12. Lipoprotein(a) in health and disease
13. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins
14. Apolipoprotein E and atherosclerosis: Insight from animal and human studies
15. The underlying molecular mechanism of apolipoprotein E polymorphism: Relationships to lipid disorders, cardiovascular disease, and Alzheimer's disease
16. Expression of lipoprotein receptors in atherosclerotic lesions
17. Common variation in the lipoprotein lipase gene: Effects on plasma lipids and risk of atherosclerosis
18. 1999 George Lyman Duff memorial lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis
19. Cholesteryl ester transfer protein and atherosclerosis
20. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal diseases, and post-transplantation
21. New perspectives on the management of low levels of high-density lipoprotein cholesterol
22. Epidemiological evidence linking plasma lipoprotein disorders to atherosclerosis and other diseases
23. Genetics of lipoprotein disorders
24. Genetic and environmental influences on LDL subclass phenotypes
25. Changing concepts of atherogenesis
26. Modified LDL - Trigger of atherosclerosis and inflammation in the arterial intima
27. High-density lipoprotein: The clinical implications of recent studies
28. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
29. Genetic basis of lipoprotein disorders
30. Genes influencing HDL metabolism: New perspectives and implications for atherosclerosis prevention
31. Genetic determinants of atherosclerosis-related dyslipidemias and their clinical implications
32. Candidate genes, small effects, and the prediction of atherosclerosis
33. Apolipoprotein E and atherosclerosis
34. Genetics of lipoprotein disorders
35. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study
36. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium
37. APOE genotype as a risk factor for ischemic cerebrovascular disease: A meta-analysis
38. Inflammation and lipid-lowering treatment
39. Lipoprotein(a) and stroke
40. Novel risk factors for atherosclerosis
41. Serum Lp(a) lipoprotein levels in patients with atherosclerotic occlusive disease of the lower extremities
42. Plasma concentration of lipoprotein(a) and the risk of future stroke
43. A prospective study of lipoprotein(a) and the risk of myocardial infarction
44. Lipoprotein (a) and cardiovascular risk
45. Lipoprotein(a) and coronary heart disease risk
46. Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study
47. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group
48. Cholesteryl ester transfer protein and atherogenesis
49. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
50. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels
51. Familial lipoprotein disorders in patients with premature coronary artery disease
52. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators
53. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
54. Prospects for genetic therapy of cardiovascular disease
55. Somatic gene therapy for dyslipidemias
56. Gene therapy for atherosclerotic cardiovascular disease: A time for optimism and caution
57. High density lipoproteins and coronary heart disease. Future prospects in gene therapy
58. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia
59. Recombinant apolipoproteins for the treatment of vascular diseases
60. Evaluation of lipoproteins/apolipoproteins as therapeutic agents for the treatment of vascular and nonvascular disease